Tumor tissues from ICB nonresponders exhibited higher levels of both tumoral USP22 and EZH2 expression and lower tumoral β2M expression when compared with biopsies from patients who were ICB responsive (Figure 6, A and D). This evidence concerns the gene EZH2 and neoplasm.